Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc > To better understand the complexity of ADCs

<< Previous

Bullboard Posts

Next >>

Comment by palinc2000on Feb 05, 2021 4:56pm

77 Views

Post# 32487698

RE:RE:RE:RE:RE:RE:RE:To better understand the complexity of ADCs

Excuse my ignorance but it seems to me that since TH has already committed to and received a may proceed letter from Fda that the rehashing of ADC vs PDC and most of the other scientific stuff adds nothing to the investment thesis ,Unfortunately or fortunately the decision to go ahead with the peptide has been vetted by the scientific team ,consuktants and the CMO at TH.I dont see how all this research and eloquent scientific terms proves anything other than some here have a scientific background
Let Phase 1 run its course and then discuss the results but the rest is hogwash imo

<< Previous

Bullboard Posts

Next >>

Pro Women’s Hockey League comes to NHL 25 in December